Response by Lee et al to Letter Regarding Article, “Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We thank Drs Iguchi and Nango for their interest in our study, which showed that pioglitazone may reduce risk of recurrent stroke and major vascular events in ischemic stroke and transient ischemic attack patients with insulin resistance, prediabetes, and type 2 diabetes mellitus.1 Their point is well taken that in sensitivity analyses, exclusion of the J-SIRIT study,2 a nonblinded small study with a potentially high performance bias, rendered the overall results statistically nonsignificant (hazard …